Fight Aging!

Today's open access paper combines a few interesting topics. Firstly, the researchers involved describe a way to deliver a short-lived messenger RNA gene therapy selectively to the innate immune cells known as macrophages. Macrophages are normally responsible for engulfing all sorts of unwanted structures in the cell, and many of the specific features that induce that behavior have been identified. Encapsulating messenger RNA into lipid nanoparticles that mimic some of the surface features of cells undergoing programmed cell death results in aggressive uptake by macrophages. Macrophages arguably make a good target for gene therapies in which the goal is to manufacture a secreted molecule of some sort, such as an antibody, and have it fairly widely and evenly distributed throughout the body. For many secreted molecules, this is quite unnecessary; injecting a single subcutaneous fat depot with a small amount of a non-targeted vector can and does work. Distribution in the body is enough of a challenge in gene therapy for any and all alternatives to be welcomed, however.

The application of this novel approach to messenger RNA therapy is in this case a reduction of circulating MMP9. The secreted molecule generated by the targeted macrophages is an anti-MMP9 antibody, directly binding to and allowing clearance of MMP9. Increased circulating MMP9 is characteristic of aging, and here researchers demonstrate that it is the cause of further issues by clearing it and observing benefits. Targeted depletion of MMP9 from circulation achieved via this antibody manufacturing approach improved the function and structure of bone and cartilage tissue in treated mice. It is of course a long road from preclinical proof of concept to therapy in the clinic, and many such demonstrations are never further developed. One might hope that this will at least attract more attention to the production of novel drugs that can much more effectively and selectively reduce circulating MMP9 than is the case for present small molecule drugs known to affect MMP9 levels.

In vivo circRNA-engineered macrophages mediate localized MMP9 neutralization to rejuvenate aged bone

Age-related bone disorders (e.g., osteoporosis, impaired fracture healing, and osteoarthritis) rank among the most common and debilitating complications in elderly populations. However, current treatment strategies are predominantly palliative, focusing on symptom management rather than addressing the underlying causes or halting disease progression. Growing evidence suggests that these disorders share a common pathophysiological foundation, driven by chronic low-grade inflammation, cellular senescence, and dysregulated tissue remodeling.

Through transcriptomic analysis of serum and bone samples from elderly human individuals, we identified matrix metalloproteinase-9 (MMP9) as a potential central and consistently upregulated effector in age-related bone dysfunction. MMP9 is well-known for its role in extracellular matrix degradation, but its persistent elevation in aged individuals and osteoporotic bone suggests a broader pathological role in skeletal aging. Despite this, its mechanistic contribution to age-related bone loss and its potential as a therapeutic target remain unexplored.

Effective clearance of MMP9 in the blood and bone microenvironment as a therapeutic target could be a highly efficient strategy for treating degenerative bone diseases. Clearly, the introduction of neutralizing antibodies is the most direct approach. However, neutralizing antibodies have limitations in terms of safety and cost-effectiveness and lack effective bone-targeting capabilities. In recent years, mRNA-based protein replacement strategies have brought revolutionary breakthroughs to the field. While mRNA-based therapeutics have revolutionized vaccinology and oncology, their clinical application in age-related degenerative diseases, particularly within orthopedic settings remains elusive.

Here, we developed an in vivo messenger RNA based antibody-engineering strategy that specifically targets macrophages, converting them into biofactories for anti-MMP9 antibodies. Central to this therapy is an apoptosis-mimicking lipid nanoparticle incorporating phosphatidylserine with an optimized formulation (aMMP9-LNP), which enhances macrophage-specific recognition and endocytosis. Leveraging inflammation-guided chemotaxis, this approach enables systemic, targeted MMP9 neutralization. In aged mice, aMMP9-LNP injected intravenously reduced stem cell senescence, boosted osteogenesis, accelerated fracture repair, and mitigated cartilage degeneration. Mechanistically, MMP9 blockade dampened the senescence-associated secretory phenotype, restored osteoblast-osteoclast balance, and lowered p21/MMP3. Biodistribution confirmed bone-targeted delivery with preserved tissue homeostasis, supporting translational potential.